Birgitta Lauri

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Andrew Spencer, Suzanne Lentzsch, Katja Weisel et al. · Haematologica · 2018 · 262 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study

M Hedenus, G Birgegård, Per Näsman et al. · Leukemia · 2007 · 200 citations

Medicine, Hematology, Pharmacotherapy +10

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group

Maria Winqvist, Anna Asklid, Per Andersson et al. · Haematologica · 2016 · 115 citations · Full text

Medicine, Oncology, Pharmacotherapy +15